1. Pharmacia&Upjohn. Reboxetine (PNU-155950E) versus placebo and fluoxetine in a controlled, randomized, double-blind, multicenter study of treatment in major depressive disorders: final report of the study protocol 97-CRBX-050, 2001. Available at http://www.iqwig.de/download/Studie_050.pdf. Accessed April 5, 2018.
2. U.S. Food and Drug Administration CfDEaR. Statistical review – Lexapro NDA 021323, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Statr.pdf. Accessed April 5, 2018.
3. Multicenter, Placebo-Controlled, Fixed-Dose Study of Citalopram in Moderate-to-Severe Depression
4. Pharmacia&Upjohn. Reboxetine, placebo, and paroxetine comparison in patients with major depressive disorder: a phase III, randomized, double-blind, placebo- and active-treatment-controlled, parallel-group, 8-week study of reboxetine, given orally twice daily to adult patients with major depressive disorder: final report of the study protocol M/2020/0047, 2001. Available at http://www.iqwig.de/download/Studie_047.pdf. Accessed April 5, 2018.
5. EliLilly. Clinical Study Summary: Study F1J-MC-HMATa, 2004. Available at https://assets.contentful.com/hadumfdtzsru/1D76MTikKkeSIuOS4SgQcq/433330f08ad190a430f5d0f2140cb4b3/Duloxetine-F1J-MC-HMAT-_Study-Group-A_.pdf. Accessed April 5, 2018.